Company

Regen

Regen BioPharma Inc

RGBP biotech USA

Quick answer

Regen is a biotech company (RGBP) headquartered in LA MESA, CA, USA with 10 tracked pipeline programs.

Pipeline (10)

Autologous (self) mononuclear cells derived from umbilical cord blood

Hypoplastic Left Heart Syndrome

Phase 2 · mab · active

1 trials project

Autologous Bone Marrow-derived Mononuclear Cells

Congenital Heart Disease

Phase 1 · mab · completed

1 trials project

Autologous mononuclear cells

Congenital Heart Disease, SRV Dependent

Phase 1 · mab · active

1 trials project

Extracellular Vesicles from Mesenchymal Stem Cells

COVID-19 Pneumonia

Phase 1 · mab · active

1 trials project

MSC-derived exosomes

Long COVID-19 Syndrome

Phase 1 · mab · active

1 trials project

autologous cell-based delivery

Hypoplastic Left Heart Syndrome

Phase 1 · mab · completed

1 trials project

Cellular Matrix / A-CP-HA Kit

Genitourinary Syndrome of Menopause

Approved · small_molecule · active

1 trials project

hyaluronic Acid + platelet-rich plasma

Knee Osteoarthritis

Approved · small_molecule · completed

1 trials project

Placebo

Knee Osteoarthritis

Unknown · small_molecule · active

1 trials project

Regen Matrix-PRP-XLHA

Knee Osteoarthritis

Unknown · other · active

Drugs (12)

acetylcysteine

ACETYLCYSTEINE

adenosine

ADENOSINE

aminophylline

AMINOPHYLLINE

betamethasone acetate

BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE

caffeine citrate

CAFFEINE CITRATE

calcium chloride

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

chlorothiazide sodium

CHLOROTHIAZIDE SODIUM

clonidine hydrochloride

CLONIDINE HYDROCHLORIDE

cupric sulfate

CUPRIC SULFATE

cyanocobalamin

CYANOCOBALAMIN

dactinomycin

DACTINOMYCIN

desmopressin acetate

MINIRIN

Patents (8)

US 12427197

Methods of producing cobalt nanoparticles and hollow metal nanospheres

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12428455

Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing via

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12427151

Compositions and method of treating cancer

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12427155

Treatment for tau-related diseases

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12426594

Cryoprotective compositions and methods for protection of a surgical site during

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12428416

ERK inhibitors and uses thereof

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12427148

Cancer treatment targeted to tumor adaptive responses to protein synthesis stres

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

US 12428463

Chimeric antigen receptors targeting abnormal glycobiology

Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

Data sources & disclaimer

This profile compiles public regulatory and patent records for informational use by pharmaceutical professionals. It is not medical advice, not investment advice, and not an official FDA, EMA, USPTO, SEC, or NIH record. NovaPharmaNews does not represent any manufacturer, sponsor, or regulator unless explicitly stated in a separate agreement.

Patent expiry and loss-of-exclusivity dates may be estimates when derived from grant date or bulk patent metadata. Confirm material dates against the USPTO, FDA Orange Book, or counsel before contractual or regulatory decisions.

Verify critical facts using the primary sources below. See our data sources policy (methodology) and privacy policy.

Last data refresh: May 23, 2026